GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

Their core work

GSK Spain's R&D unit in Tres Cantos (Madrid) is the pharmaceutical giant's dedicated infectious disease research arm, with deep focus on tuberculosis drug development and antimicrobial resistance. They run preclinical and clinical development pipelines for TB drug candidates, advancing compounds from early discovery through Phase II trials. They also contribute to gram-negative antibiotic programs and have explored neglected tropical disease treatments, including Chagas disease via lipid nanoparticle drug delivery. Their H2020 involvement reflects GSK's commitment to diseases where commercial incentives alone are insufficient — TB, AMR, and neglected infections.

What they specialise in

How they've shifted over time

In 2017, GSK Spain entered H2020 with a broad infectious disease focus — coordinating their own TB drug candidate pipeline (anTBiotic) while contributing to consent ethics for vulnerable populations in vaccine trials (I-CONSENT). From 2019 onward, the focus sharpened dramatically: four of five later projects target tuberculosis or antimicrobial resistance, with increasing emphasis on computational trial design and multi-partner drug development platforms. The trajectory shows a deliberate shift from standalone drug discovery toward large-scale collaborative programs that combine preclinical development, clinical pharmacology, and AI-driven trial optimization.

GSK Spain is moving from traditional pharma R&D toward participation in large, multi-partner drug development platforms that use AI and innovative trial designs to accelerate TB and AMR treatments — making them an increasingly attractive partner for computational and clinical collaborators.

How they like to work

GSK Spain operates primarily as a participant in large consortia (4 of 7 projects), joining major multi-partner initiatives like ERA4TB and UNITE4TB that run through 2026-2028. They have coordinated two smaller, focused projects (anTBiotic, LYMPHVECs), showing they can lead when driving their own drug candidates forward. With 85 unique partners across 17 countries, they function as a well-connected industry node — the kind of pharma partner that brings clinical development infrastructure and regulatory experience to academic-led consortia.

Extensive European network spanning 85 unique partners across 17 countries, reflecting GSK Spain's role in several of H2020's largest infectious disease initiatives. Their partner base likely includes major academic medical centers, biotech SMEs, and public health organizations across Western and Eastern Europe.

What sets them apart

GSK Spain brings something rare to H2020 consortia: the clinical development infrastructure and regulatory muscle of a top-5 global pharma company, deployed specifically on diseases with limited commercial return (TB, neglected tropical diseases, AMR). Their Tres Cantos campus is one of the few pharma R&D sites globally dedicated to diseases of the developing world. For academic partners, they offer a credible path from lab discovery to Phase II clinical trials — the "valley of death" where most drug candidates fail without industrial partners.

Highlights from their portfolio

• anTBiotic
  GSK Spain's flagship as coordinator — EUR 704,871 in EC funding to advance their own TB drug candidates to clinical proof of concept, representing their core mission.
• UNITE4TB
  Massive consortium running through 2028 that combines AI, innovative trial design, and clinical pharmacology for TB treatment — signals where GSK Spain's future collaboration focus lies.
• GNA NOW
  Long-running program (2020-2026) tackling the critical gram-negative antibiotic gap, showing GSK Spain's commitment beyond TB to the broader AMR crisis.